ロード中...
A screen to identify drug resistant variants to target-directed anti-cancer agents
The discovery of oncogenes and signal transduction pathways important for mitogenesis has triggered the development of target-specific small molecule anti-cancer compounds. As exemplified by imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid Leukemia (CML)-associated Bcr-Abl kinase, the...
保存先:
| 出版年: | Biol Proced Online |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2003
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC248481/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14615817/ https://ncbi.nlm.nih.govhttps://doi.org/10.1251/bpo63 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|